Health

Trying not one, but a three-drug combination to help engineered T cells fight cancer

Trying not one, but a three-drug combination to help engineered T cells fight cancer

NEW ORLEANS — For years, Kristin Anderson has been trying to push immunotherapy to work in ovarian cancer, only to see immune tool after tool fail to crack the tumors. But now, Anderson has new data from a preliminary approach that some experts called both thought-provoking and a little controversial: a combination of three immune checkpoint inhibitors and a batch of engineered T cells.

The work started off with a simple question, said Anderson, a postdoctoral scientist at the Fred Hutchinson Cancer Center: Is it possible to engineer T cells to attack ovarian tumors? Anderson started by modifying T cells to carry a receptor that would recognize mesothelin — a protein common in several cancer types including ovarian. That way, these modified immune cells would be more likely to infiltrate the tumors and, hopefully, start cleaning up the cancer.

Most Popular

To Top